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Summary 
Bradykinin (BK) is a peptide mediator released in in- 
flammation that potently excites sympathetic neurons. 
We have studied the mechanism of this excitation in 
dissociated rat sympathetic neurons and found that at 
low nanomolar (ECs0 = 0.9 nM) concentrations, BK 
inhibited the M-type K + current IK(M). Studies with the 
selective antagonist Hoe140 revealed that this effect 
was mediated via the B2 receptor subtype, and mRNA 
encoding this receptor was identified in these neurons 
by RT-PCR. Ix(M) inhibition was unaffected by Pertussis 
toxin or microinjection of antibodies to Gao but was 
selectively in hibited by microinjection of antibodies to 
G~q~11. Thus, BK is the most potent M current inhibitor 
yet described in mammalian neurons, and BK inhibi- 
tion of M current is mediated by a G protein pathway 
similar to that activated by muscarinic acetylcholine 
receptors. 
Introduction 
The nonapeptide bradykinin (BK) is formed from plasma 
protein precursors following tissue injury and is consid- 
ered an important mediator of inflammation and hyperal- 
gesia (Lewis, 1970; Regoli and Barab6, 1980; Hall, 1992; 
Dray and Perkins, 1993). There is evidence that activation 
of sympathetic nerves may contribute to some of its ef- 
fects, including hyperalgesia and plasma extravasation, 
as these are abolished by sympathectomy (Levine et al., 
1986; Coderre et al., 1989; Lee et al., 1991). Such effects 
are thought to be mediated by a stimu[atory action of BK 
on sympathetic terminals, resulting in the release of 
prostanoids (Coderre et al., 1989; Lee et al., 1991), which 
can then induce sensitization of nociceptors (see Dray and 
Perkins, 1993). There has also been speculation that BK 
may have an involvement in the etiology of sympathetically 
maintained pain (McMahon, 1991). 
The ability of BK to stimulate sympathetic neurons was 
described many years ago (Lewis and Reit, 1965, 1966; 
Trendelenburg, 1966), but the mechanism of this stimula- 
tion is unknown. Studies on other neurons and neural cell 
lines suggest a number of possibilities, including activa- 
tion of a cation conductance ('l'ertoolen et al., 1987; Bur- 
gess et al., 1989; Neuhaus et al., 1991), activation of a 
Ca2÷-dependent CI- conductance (Dunn et al., 1991), 
which would be expected to depolarize rat sympathetic 
neurons (Adams and Brown, 1975), inhibition of a Ca 2÷- 
dependent K ÷ conductance (Weinreich, 1986), and inhibi- 
tion of the M-type voltage-gated K ÷ conductance (Higa- 
shida andBrown, 1986, 1987; Villarroel et al., 1989). 
In the present experiments, we have examined the excit- 
atory action of BK on dissociated rat sympathetic neurons. 
We find that it is an extremely potent inhibitor of the M 
current (IKIM)), and that it works in a qualitatively similar, 
but quantitatively and kinetically different, manner to mus- 
carinic acetylcholine receptor stimulants. 
Results 
Excitation and M Current Inhibition by Low 
Concentrations of BK 
In current-clamp studies, the average resting potential in 
our sample of rat cultured superior cervical ganglion (SCG) 
neurons was -56 mV -4- 1 mV (n = 37). BK produced a 
small (4-6 mV) depolarization of SCG neurons and in- 
duced repetitive action potential discharges during injec- 
tion of depolarizing current (Figure 1). This accords with 
the excitatory effect of BK previously noted in cat (Haefely, 
1970) and rabbit (Wallis and Woodward, 1974) SCG. This 
response is reminiscent of that seen with rnuscarinic ace- 
tylcholine receptor agonists (Brown and Constanti, 1980) 
and suggests that BK might inhibit IKIM~ (Constanti and 
Brown, 1981). Consistent with this idea, in voltage-clamp 
experiments with the holding potential at about -25 mV 
(where there was a standing outward current), application 
of low nanomolar concentrations of bradykinin produced a 
slowly developing reduction of this outward current (Figure 
2A). This BK-induced change in current was larger at de- 
polarized potentials than at hyperpolarized potentials, 
implying a fall in effective input conductance (Figure 3). 
Inspection of current records obtained during hyperpolar- 
izing voltage steps revealed that the BK effect was associ- 
ated with inhibition of the voltage-gated K ÷ current IK(M), 
since the slow relaxations during deactivation and re- 
activation of this current were reduced (Figure 2B; see 
Adams et al., 1982). In accordance with this, the current- 
voltage curves (Figure 3) showed a reduction of the out- 
ward rectification ormally observed at potentials positive 
to -70 mV (the threshold for IK/M) activation). In current- 
voltage relationships, we observed small (< 100 pA) inward 
currents in response to 1 nM BK at potentials more nega- 
tive than -70 mV (three of five cells) and small (<50 pA) 
outward currents in the remaining two cells. Thus, it ap- 
pears that inhibition of outward IK(M) accounts for a very 
substantial proportion of the apparent inward current pro- 
duced by BK, as this was itself highly voltage sensitive 
(Figure 3). 
These effects parallel those of muscarinic acetylcholine 
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Figure 1. Bradykinin Induces Repetitive Firing of Action Potentials 
The left trace (control) shows a record of membrane potential of an 
SCG neuron recorded in current clamp using the perforated-patch 
technique. Injection of depolarizing current (0.3 nA for 500 ms, at the 
arrow) depolarized the neuron and evoked a single action potential. 
Application of 10 nM BK produced a small depolarization (5 mV in 
this cell), which was countered by injection of hyperpolarizing current 
sufficient to return the cell to its original resting membrane potential 
(-67 mV). When the same depolarizing current was injected in the 
presence of BK, repetitive action potential firing was seen (right trace). 
This recording was made from a cell maintained at 32°C. Action poten- 
tial amplitudes are truncated by the digitization sampling rate (3 kHz). 
receptor agonists, such as muscarine or oxotremorine-M 
(oxo-M), previously reported in these neurons (Constanti 
and Brown, 1981; Marrion et al., 1989; Bernheim et al., 
1992; Caulfield et al., 1994). However, there were two dif- 
ferences between the actions of BK and oxo-M. First, the 
effects of BK were much slower in onset. Thus, in five 
experiments in which BK (10 nM) and oxo-M (3 I~M) were 
directly compared, the half-times for reduction in outward 
currents at a holding potential of -25  mV were 22 _+ 2.5 s 
for BK and 7.5 _ 0.4 s for oxo-M. This did not seem to 
be due to slow equilibration, since (in four of these five 
cells) the initial response to BK was a small outward cur- 
rent that developed as rapidly as the response produced 
by oxo-M (which was purely a reduction in standing out- 
ward current; see Figure 2C). The BK-induced outward 
current was not studied further because of its small size 
and irregular occurrence. Second, compared with recov- 
ery from oxo-M, recovery from inhibition of IKIM) by BK was 
frequently slow and incomplete, especially at higher con- 
centrations (see Figure 2A; Caulfield et al., 1994). 
Inhibition of IK(M) by BK was evident at concentrations as 
low as 0.1 nM, with a plateau at 10-30 nM. The computed 
maximum inhibition was 74.1% __. 10.5% , with half- 
maximum inhibition at 0.9 nM (Figure 4A). The rate of 
onset of IK(M) inhibition by BK was also concentration de- 
pendent; the half-time to the full development of the BK 
effect being approximately 40 s for 1 nM BK, and approxi- 
mately 20 s for 10 nM BK (Figure 4B). The concentrat ion-  
effect curve for inhibition of IK(M) by BK in Figure 4 was 
constructed by applying single concentrations of BK to 
individual cells, thereby minimizing errors due to waning 
reponses to repeated applications of BK on the same cell 
(tachyphylaxis). Tachyphylaxis was not significant at the 
lower range of the concentration-effect curve; for exam- 
ple, in five cells, the IK~M) inhibitions in response to two sub- 
sequent applications of 1 nM BK were 35.6% + 3.7% and 
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Figure 2. Bradykinin Inhibits the M-Type K ÷ Current 
(A) Membrane current (pA) at the holding potential (-24 mV, open 
circles) and IK(M) deactivation amplitude at the command potential (-54 
mV, closed circles) plotted against time (s). Perfusion with 10 nM BK 
at time 0 (indicated by the bar) caused a slowly developing reduction 
in both the holding current and the amplitude of IKIM) deactivation relax- 
ations. Recovery upon washing out BK was slow and partial. 
(B) Example current records from the same cell as (A). IKIM) deactivation 
relaxations during a 1 s voltage step from -31 to -61 mV in control 
solution (c) are reduced by perfusion with 10 nM BK. The dotted line 
indicates 0 pA. 
(C) The continuous change in membrane current (nA) at the holding 
potential (-26 mV) during perfusion of oxo-M (3 p_M) and, after achiev- 
ing almost complete recovery on washing out oxo-M, the response to 
a subsequent application of BK (10 nM). 
34.4% -+ 4.7% (n = 5). However, responses to higher 
concentrations of BK were not reproducible for a given 
cell; for example, in three cells, the IK(M)inhibition for a first 
application of 10 nM BK was 52.7% __+ 3.0%, whereas 
the inhibition with the second application was significantly 
lower (a mean of 35% of the first response; p < .01, paired 
t test). This contrasts with IK(Mi inhibition by a maximal ly 
effective concentration of oxo-M (3 pM; Caulfield et al., 
1994), in which a first application produced 84.3% _+ 5.7% 
reduction of current, whereas a second application elicited 
an almost identical response (83.3% _ 5.2%; n = 3). 
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Figure 3. EffectofBKontheSteady-StateCurrent-VoltageRelationship 
Current recorded during a voltage ramp from -19 mV to -110 mV 
(-10 mV/s) in control solution (c) and in the presence of 1 nM and 10 
nM BK (+1 nM and +10 nM, respectively). In this cell, the inhibition 
of IK(M) by these two concentrations of BK (measured from deactivation 
relaxations) was 26% and 68%, respectively. Comparable inhibition 
of leak-subtracted current by BK was noted during the voltage ramp 
at potentials of -20 mV (30% and 620/o) and -50 mV (31% and 59%). 
Closed circles represent he steady-state current-voltage relationship 
in the same cell, obtained by recording end-of-pulse current during 1 s 
negative voltage steps in increments of-10 mV from the holding poten- 
tial (-19 mV). The inset shows BK-sensitive current across the voltage 
range, obtained by subtracting current traces in the presence of BK 
(1 and 10) from control current (c). In control solution, the graph of 
evoked current overlapped ata points obtained by estimating steady- 
state currents during discrete 1 s steps to command voltages within this 
range. This shows that this voltage ramp protocol gave an adequate 
measure of current over the activation range for IK<M) (more positive 
than -70 mV); both concentrations of BK reduced evoked current over 
this range. Also, the BK-sensitive current across this voltage range 
(obtained by subtraction of current in the presence of BK from control 
current) closely resembled the control current. 
IK(M) Inhibition Is Mediated by the B2 Receptor 
The effect of the highly selective B2 receptor antagonist 
Hoe140 was investigated by first estimating IK(M/inhibition 
in response to 1 nM BK, allowing recovery of IK(M) after 
washing out the BK, then repeating the application of 1 
nM BK in the presence of the antagonist. Hoe140 (100 nM, 
applied for 5 min; n = 4) reduced the response to 1 nM 
BK by 91.8 % _+ 3.5% (Figure 5). Usually, the BK response 
did not recover even after washing in antagonist-free solu- 
tion for 30 min (n = 3), although partial reversal of the 
Hoe140 antagonism was observed in one cell after wash- 
ing for 90 rain (Figure 5). 
Reverse transcription-polymerase chain reaction (RT- 
PCR) analysis of RNA extracted from rat superior cervical 
ganglia and rat dorsal root ganglia, with primers derived 
from noncoding and coding exons of the rat BR2 gene, 
revealed the presence of BR2 transcripts in both tissues 
(Figure 5C). 
B2 Receptor-Mediated Inhibition of IK(M) Involves 
G.qm Protein(s) 
In these experiments, we used a test concentration of 1 
nM BK, as there was no waning of the response to this 
concentration of BK for a given cell or between cells in 
the same dish. Also, a submaximal response to 1 nM BK 
would be a sensitive assay for any change in receptor-G 
protein coupling efficiency. Inhibition of IK(MI by 1 nM BK 
(38.9% _+ 2.8%; n = 21) was not affected by pretreatment 
of neurons with Pertussis toxin (PTX; 500 ng/ml for 15- 
20 hr; 39.7% _+ 3.3% inhibition; n = 6) or injection of 
anti-Gao antibody (39.7% _+ 2.6% inhibition; n = 9). How- 
ever, in neurons injected with anti-G.qm antibody, the BK 
inhibition of IK(MI was reduced to 19.5% _+ 5.8% (n = 6). 
This was a significant reduction compared with the BK 
response in anti-G~o injected neurons (p < .05, t test; 
Figure 6). 
We also determined whether the inhibitory effect of the 
anti-G~qm antibody on IK/M/ inhibition by BK could be oc- 
cluded by injecting a mixture of the antibody and the immu- 
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Figure 4. Concentration Dependence of the 
BK Inhibition of ]K(M) 
(A) Concentration-response relationship for 
IK(M) inhibition by BK. Data points represent 
mean (4- SEM; n = 3-21)inhibition of IK(M)(y) 
in response to different BK concentrations (A), 
plotted with a logarithmic abscissa scale. The 
solid line is the best fit to the data of the function 
y = m x 10 n * '°g(A)/(10n × ,og{AI + 10n x ,og(KI), with 
weight (l/sem2), where m is 74..1 + 10.0, log(K) 
is -9.05 4- 0.2, and n is 0.52 4- 0.14. Curve- 
, fitting was done using SigmaPIot 5 (Jandel Sci- 
entific). 
(B) Membrane current at the holding potential 
recorded every 10 s during application of 1 nM 
BK (open circles, V. = -26 mV) and 10 nM 
BK (filled circles, Va = -24 mV, same cell as 
Figure 1A). 
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Figure 5. BK Acts at the B2 Receptor to Inhibit IK(M) 
(A) Example current records showing h<(M) deactivation relaxations dur- 
ing a 1 s voltage step from -25 mV to -55 mV. The traces at left 
(control) are superimposed currents before (c) and during application 
of 1 nM BK (d). The middle traces (+Hoe140, 100 nM) show the current 
after recovery from the previous BK application, but now in the pres- 
ence of Hoe140 (applied 5 min previously [c}). With the antagonist 
present, there was virtually no change in current when BK was applied 
(d). The right trace shows a current response (c)90 min after superfus- 
ing with antagonist-free solution, when application of BK now produces 
detectable inhibition of IKIM) (d). The dotted lines represent he zero 
current level. 
(B) A bar graph showing data pooled from four cells using the protocol 
for Hoe140 application described above. Inhibition of IK(M) by 1 nM BK 
was greatly reduced (p < .02, paired t test) in the presence of 100 nM 
Hoe140. 
(C) Analysis of RNA extracted from superior cervical g nglia (SCG) 
and dorsal root ganglia (DRG) from 17-day-old rats. Lanes 1 and 2 
show a 300 bp amplification product obtained with cDNA from SCG 
and DRG, respectively. Lane 3 shows the absence of any amplification 
product with water as control template. The DRG sample was used 
as a positive control for amplification of B2 receptor mRNA, as B2 
receptor-mediated responses are well characterized in this tissue (see 
Hall, 1992). 
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Figure 6. Inhibition of IK(M) by BK Involves G~qm Protein(s) 
(A) Example current records showing IKIMI deactivation relaxations. The 
left traces show superimposed control current (c) and current reduced 
in the presence of 1 nM BK (d) in an SCG neuron that had been injected 
with anti-G=o antibody. The traces at right show control current (c) and 
a much smaller reduction f current by 1 nM BK (d) in a neuron injected 
with anti-G~q/~l antibody. 
(B) The graph shows pooled ata for IKCM) inhibition in response to 1 
nM BK from nine cells injected with anti-G~o antibody (open bar) and 
eight cells injected with anti-Goq~ antibody (closed bar). The BK re- 
sponse was significantly reduced (p < .05; asterisk) in the anti-G:qm 
antibody-injected group. 
I 
of IK(M)in the group injected with antibody pl us peptide was 
23.5% _+ 4.4% (n -- 10; significantly greater than the 
antibody alone group, p < .05; Figure 7). The reversal 
of the antibody effect by immunogenic peptide was not 
complete, as BK inhibition in the peptide plus antibody 
injected cells was still significantly less (p < .05) than in 
cells injected with peptide alone. None of the above injec- 
tion procedures affected the amplitude of IK(M) deactivation 
relaxations (mean amplitudes ranged from 152 pA to 228 
pA, with standard errors of 11-22 pA). 
nogenic peptide to preabsorb the anti-G~qm antibody. In- 
jection of peptide alone (1 ~g/ml) did not affect the BK 
inhibition of IK(M) (40.1% --+ 5.0%; n = 9) when compared 
with either uninjected cells or cells injected with anti-Goo 
antibody. In this experimental series, injection of anti-G~qm 
antibody greatly reduced the BK response (5.9% _ 2.2% 
IK(M) inhibition; n -- 9; p < .001), and this effect of the 
anti-G~q~ antibody was partially reversed in cells injected 
with a combination of antibody and peptide; BK inhibition 
Discussion 
We have found that low nanomolar concentrations of BK 
inhibit IK(M)in rat sympathetic neurons. Current-voltage 
curves (see Figure 3) suggest that reduction of this out- 
ward current is the predominant BK effect. Therefore, IK(M) 
inhibition iS probably responsible for the ganglion excita- 
tion previously reported (Lewis and Reit, 1965, 1966; Tren- 
delenburg, 1966; Haefely, 1970; Wallis and Woodward, 
1974) and for the small depolarization and increase in ac- 
tion potential firing noted in the present experiments. This 
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(A) Example current records howing IK(M~ inhibition by 1 nM BK in cells 
injected with peptide alone (1 ~.g/ml), anti-G~qm antibody alone, or 
anti-G~qm antibody plus peptide (1 ~g/ml; eft to right, respectively). 
iK~M) deactivation relaxations were measured uring a 1 s, -30 mV 
step from holding potentials of -27, -28, and -27 mV respectively, 
in control solution (c), then after perfusion with 1 nM BK (d). The dotted 
line indicates 0 pA. 
(B) Bar graph showing inhibition of IKIM) by 1 nM BK for each of the 
above groups. The response to BK in cells injected with peptide only 
(open bar; n = 9) was significantly reduced (p < .001; asterisks) in 
neurons injected with anti-G~¢~ antibody (closed bar; n = 9). When 
peptide and antibody were injected together, the response to BK 
(hatched bar; n = 10) was significantly greater than in the antibody- 
alone group (p < 0.05; single asterisk). 
is consistent with the action of BK previously observed in 
some neural cell lines, such as PC12 cells (Villarroel et 
al., 1989) and neuroblastoma-derived cells (Higashida nd 
Brown, 1986, 1987). However, our finding of this action 
of BK in sympathetic neurons may have direct relevance 
to the proposed role of the sympathetic nervous system in 
inflammatory processes (for review, see Dray and Perkins, 
1993). 
We obtained no evidence for activation of a substantial 
cation conductance, as has been reported in sensory neu- 
rons (Burgess et al., 1989; Dunn and Rang, 1990). Al- 
though in some neurons, BK evoked a small inward cur- 
rent, this was inconsistent. Similar additional inward 
currents have been detected with agonists that inhibit M 
current in bullfrog sympathetic neurons (Jones, 1985). In 
some neurons, the inward current resulting from IK(M)inhibi- 
tion was preceded by a small outward current. This may 
have represented the Ca2---activated K÷ current observed 
more prominently in neuroblastoma cells (Higashida and 
Brown, 1986), but because of its small size and irregularity, 
we were unable to study this in detail. 
There are two bradykinin receptors (B1 and B2) that could 
conceivably mediate BK inhibition of IK(M), although B1 re- 
ceptors do not seem to be involved in normal physiological 
responses (Hall, 1992; Dray and Perkins, 1993). Consis- 
tent with this, inhibition of IK/MI by BK in SCG neurons was 
mediated by the Bz receptor subtype, as evidenced by the 
potent inhibitory effect of the selective B2 receptor antago- 
nist Hoe140 on BK responses. This conclusion is sup- 
ported by our demonstration of the presence of mRNA 
encoding the B2 receptor in whole SCG, although we can- 
not exclude the possibility that some of this signal repre- 
sents B2 mRNA expressed in cells other than the principal 
neurons. 
Bradykinin receptors can couple to many biochemical 
pathways, via both PTX-sensitive and PTX-insensitive G 
proteins (Hall, 1992). We suggest that the principal G pro- 
tein mediating BK inhibition of IK(M) in SCG neurons is G°q 
or G,I~ (or both) because the BK response was significantly 
reduced in neurons that had been injected with an anti- 
body raised against he C-terminal decapeptide sequence 
common to these G proteins. As this sequence is thought 
to represent he G-protein domain to which activated re- 
ceptors couple, it is predicted that such antibodies will 
specifically inhibit responses mediated by the G proteins 
against which they are directed. The specificity of effect 
of the anti-G,~ antibodies in our study was indicated by 
a reduction in their efficacy when coinjected with a deca- 
peptide corresponding to the immunogenic sequence. 
This would be expected to sequester the antibodies (if 
present in sufficient excess), thereby preventing their bind- 
ing to endogenous G,qm in the SCG neurons. Further infer- 
ential evidence that IK(M) inhibition by BK is via G,,~I~ (rather 
than a PTX-sensitive G protein) comes from our parallel 
observation that the BK response was not modified by PTX 
pretreatment of SCG neurons or by injection of antibody 
raised against he C-terminal decapeptide of Goo. The lack 
of effect of these treatments cannot be attributed to incom- 
plete action of PTX or to lack of activity of the anti-G,o 
antibody, as we have previously demonstrated virtually 
complete PTX-induced ADP-ribosylation of susceptible G 
proteins in SCG neurons and inhibition of a different neuro- 
transmitter response (norepinephrine suppression of volt- 
age-activated Ca 2+ current) by the anti-G,o antibody in 
these cells (Caulfield et al., 1994). Our conclusion that 
the B2 bradykinin receptor couples to G~¢~ accords with 
previous demonstrations that stimulation of phospholi- 
pase C activity and activation of Ca2+-activated K÷ conduc- 
tance in NG108-15 neuroblastoma hybrid cells can be 
mediated by this G protein (Gutowski et al., 1991; Wilk- 
Blaszczak et al., 1994). 
Our finding that BK inhibits I(~M through G~qm is paral- 
leled by similar findings for the M~ muscarinic acetylcho- 
line receptor in SCG neurons (Caulfield et al., 1994), per- 
haps suggesting that the BK response, like the muscarinic 
response (Selyanko et al., 1992), is mediated by a diffus- 
ible messenger. However, there are a number of aspects 
of the BK IK(M) inhibition that are clearly different from the 
IK(M) inhibition produced by muscarinic receptor agonists. 
Neuron 
404 
Thus, the BK response has a significant onset latency 
(at least 10 s), is slow to develop (taking at least 60 s to 
asymptote), and reverses slowly and often incompletely. 
By contrast, IxiM) inhibition by oxo-M starts to develop soon 
after agonist application, reaches its maximum in 10-30 s, 
and usually reverses within 5 rain. In part, these differ- 
ences might reflect a high binding affinity of bradykinin 
for its receptor with associated slow dissociation, which 
would result in slow onset of response. Thus, if it is as- 
sumed that the dissociation constant of BK for its receptor 
is 1 nM (not unreasonable for a peptide agonist) and the 
microscopic association constant for binding is 107 M-1s -1 , 
the time constant for inhibition of IX(M) would be 10 s at 10 
nM BK, which is not far off our 22 s time constant. The 
long latency in response onset could also be the conse- 
quence of a slow rise in the (putative) intracellular messen- 
ger, which needs to reach a threshold level before IXIM) 
is inhibited. Similar concentration-dependent lag times to 
response were noted by Neher and colleagues for intracel- 
lular Ca 2+ elevations in response to agonist activation of 
transfected muscarinic receptors in neuroblastoma cells 
(Neher et al., 1988). Another notable difference between 
the BK and oxo-M inhibitions of IK(i) is the tachyphylaxis 
seen only with high concentrations of BK (10 riM), whereby 
a prior exposure to BK greatly reduced responses to a 
subsequent agonist application. It could be argued that 
this tachyphylaxis is not the result of desensitization, as 
Ix(M) inhibition was maintained during agonist applications 
that were usually at least 2 min, and often longer. However, 
we can not exclude the possibility that the apparent achy- 
phylaxis is in fact a slowly developing desensitization oc- 
curring at receptors still occupied by agonist (even though 
the agonist has been washed out). It is interesting in the 
context of these slow and poorly reversible effects of BK 
that Shapiro et al. (1994) have recently reported similar 
slow onset and offset kinetics and tachyphylaxis for the 
inhibition of voltage-gated Ca 2+ currents by activation of 
another peptide receptor, the angiotensin AT1 receptor, 
in SCG neurons. 
To conclude, we have observed a powerful inhibitory 
action of BK on IK(M) in sympathetic neurons; indeed, BK 
is the most potent inhibitor of this K + current so far re- 
ported. This effect can account for the previously reported 
excitation of sympathetic neurons (Lewis and Reit, 1965; 
1966; Trendelenburg, 1966; Haefely, 1970; Wallis and 
Woodward, 1974). It is noteworthy that the concentrations 
of BK required to inhibit Ix(M) are well within the range of 
those found in inflammatory exudates (see Regoli and Bar- 
abe, 1980). Hence this effect may well contribute to the 
suggested role of sympathetic excitation in inflammation 
(Dray and Perkins, 1993) and pain (McMahon, 1991). 
Experimental Procedures 
Cell Culture 
Superior cervical ganglia were isolated from rats (15-19 days old), 
and cells were dissociated and cultured for 1-3 days, as described 
previously (Selyanko et al., 1992). Cells were plated on grid-marked 
plastic dishes (coated with laminin) to facilitate localization of injected 
neurons. For injections and recordings, cells were superfused with a 
modified Krebs' solution containing 120 mM NaCI, 3 mM KCI, 2.5 mM 
CaCI2, 1.2 mM MgCI2, 23 mM NaHCO3, 11 mM glucose, 5 mM HEPES, 
and .5 p.M tetrodotoxin. When bubbled with a mixture of 95% 02/5% 
CO~, the pH of this solution was 7.36. Experiments were performed 
at room temperature (20°C-25°C). 
Antibody Injections 
Antisera for injections were raised in New Zealand white rabbits as 
described previously (Goldsmith et al., 1987). Injections were made 
using high resistance (>30 MQ) electrodes, with the application of 
gentle pressure to expel the solution. Neurons were injected with one 
of the following: antiserum raised against the C terminal decapeptide 
sequence of the Go (z subunit (OC2); antiserum raised against the 
C-terminal decapeptide sequence common to the G~ and Gll ~ sub- 
units (CQ1); a decapeptide sequence (1 p.g/ml) corresponding to the 
common C-terminal decapeptide sequence of Gq and GI~ ~ subunits 
(immunogenic peptide); a combination of CQ1 and immunogenic pep- 
tide (1 ~g/ml). 
Undiluted antisera, or antisera plus immunogenic peptide were coin- 
jected with a fluorescein isothiocyanate-labeled dextran (FITC- 
dextran; 10 kDa; Molecular Probes) to allow verification of injection 
using a fluorescence microscope (Nikon Diaphot 300). Only neurons 
showing bright fluorescence after injection were used for recordings. 
In initial experiments comparing effects of anti-G~o and anti-Goq~l anti- 
bodies, cells were coinjected with 1% FITC-dextran. However, we sub- 
sequently found that 0.1% FITC-dextran gave sufficient fluorescence 
to allow visualization for up to 6 hr postinjection, so we used this 
concentration in later experiments with injections of CQ1 combined 
with immunogenic peptide. 
IK(a) Recordings 
Whole-cell currents were recorded using the amphotericin perforated 
patch method (Rae et al., 1991). Patch pipettes (2-5 M~) were front- 
filled by dipping the tip into a filtered solution containing 80 mM 
K-acetate, 30 mM KCI, 3 mM MgCI2, and 40 mM HEPES (adjusted to 
pH 7.2 and 280 mOsm) for 20-60 s and then back-filled with the same 
solution containing 50 p,g/ml amphotericin (Sigma; in 0.2o/o dimethyl 
sulfoxide). After obtaining seals of >2 GQ resistance, permeabilization 
with amphotericin usually achieved access resistances of <15 MQ. 
To measure IK(M) amplitude, neurons were voltage clamped using a 
switching amplifier (Axoclamp 2A or 2B, Axon Instruments; witching 
frequency 3-6 kHz), at potentials of -20 mV to -30 mV to activate 
IK(M), and the slow IK(M) deactivation relaxation was revealed by stepping 
to -55 mV for 1 s. In some experiments, current responses were re- 
corded to voltage ramps between about -110 mV and -20 mV, at a 
ramp rate of -10 mV/s (from a holding potential of around -20 mV). 
These experiments were done using external solution containing 1 
mM CsCI to block inward rectifier currents activated at potentials more 
negative than about -90 inV. Voltage command protocols and data 
acquisition were carried out using pClamp software (Axon Instru- 
ments). A liquid junction potential of -6 mV (outside with respect to 
inside) has not been accounted for in measurements of membrane 
potential. 
Drugs (bradykinin, Bacbem; oxotremorine msthiodide, RBI) were 
applied directly to the locality of the cell under study via a fine tube 
(diameter, 50 p,m) positioned about 1 mm from the cell. Prior to applica- 
tion, drug solution was continually removed by vacuum suction applied 
to a second tube glued alongside the drug application tube. Drug was 
delivered when the vacuum was released. The time for equilibration 
of drug concentration at the cell was less than 6 s, as determined by 
application of a solution containing 37 mM additional KCI (to set the 
reversal potential for K + at -25 mV) and measuring the delay to nega- 
tion of the standing outward K + current activated at a holding potential 
of -25 inV. On reapplying the vacuum, complete recovery of current 
was seen in under 30 s. All data are presented as mean _+ standard 
error. 
RNA Analysis 
RT-PCR were carried out as described by Steel and Buckley (1993). 
Sympathetic ganglia and dorsal root ganglia total RNA was extracted 
according to the method of Chomczynski and Sacchi (1987). RNA 
was reverse transcribed using AMV-RT (Seikagaku) and subsequently 
amplified using Taq polymerase (Promega). The primers used for am- 
plification were derived from cDNA sequence (Mclntyre et al., 1993; 
EMBL database accession number X69682). Primer sequences were: 
B2 197s, GACATCACCGGCCAGCCCTTG; B2 198as, GGTGACGTT- 
B2 Bradykinin Receptors Inhibit IK(M) via Goq~ 
4O5 
GAACATTTCGAT. B2 197s was derived from an upstream noncoding 
exon and B2 198as from the coding exon. 
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